Staff and Wire Reports
Monday, 31 August 2009 17:34
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) jumped on twice the average volume today.
Shares for the biopharmaceutical company, which focuses on pioneering novel cancer therapies with a focus primarily in the areas of hematology-oncology and urology, are under a heavy accumulation which is related to Spectrum’s dealings with the FDA, seeking approval for ZEVALIN in treating non-Hodgkin´s lymphoma (NHL).
According to many, SPPI's alliance with Allergan Inc. (NYSE: AGN) has added to speculation about a possible buyout of SPPI.
In addition, if approved by the U.S. Food and Drug Administration (FDA), the market for SPPI's drug candidate ZEVALIN could reach more than $1 billion at its market saturation.
SPPI has another FDA decision due next month and they have a fully developed commercial infrastructure that is responsible for the sales and marketing of two drugs in the United States- ZEVALIN, a form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin’s Lymphoma (NHL), and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma..
Its lead developmental drug is apaziquone (formerly EOquin), which is presently being studied in two large phase III clinical trials for non-muscle invasive bladder cancer under that strategic collaboration with Allergan Inc. Another drug, ozarelix is in a phase II clinical trial for benign prostatic hypertrophy (BPH).
SPPI operates in the most rapidly growing segment of treatment in the pharmaceutical market.
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites